New Study Identifies the Optimal Dose of Intravenous Vitamin C for Future Anticancer Clinical Trials
The use of vitamin C to treat cancer patients first became popular in the 1970s as a result of the work of Nobel laureate Linus Pauling. However, studies conducted with orally dosed supplements did not demonstrate any clinical benefit in cancer patients, most likely due to the finding that the levels of orally administered vitamin C delivered to a patient’s bloodstream were considerably lower than the levels needed to kill cancer cells in either test tube or animal models. Recent studies in which vitamin C was administered intravenously (by IV) resulted in higher levels delivered to the patients’ bloodstream suggest that vitamin C may, in fact, promote anticancer activity.









0 Comments